Transforming Growth Factor β3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas

Reproductive Sciences

Volumn 16, Issue 12, 2009, Pages 1153-1164

  Norian, John M ^a,b   Malik, Minnie ^a   Parker, Candace Y ^a,b   Joseph, Doina ^a   Leppert, Phyllis C ^c   Segars, James H ^a,b   Catherino, William H ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Extracellular matrix.; Immortalized cells; Leiomyomas; TGF 3; Versican variants

Indexed keywords

GLYCOSAMINOGLYCAN; MESSENGER RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA3; VERSICAN;

ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UTERUS MYOMA; WESTERN BLOTTING;

BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL LINE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSAMINOGLYCANS; HUMANS; LEIOMYOMA; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA3; UP-REGULATION; UTERINE NEOPLASMS; VERSICANS;

EID: 70450205241     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719109343310     Document Type: Article

References (74)

1. Leppert PC, Baginski T., Prupas C., Catherino WH, Pletcher S., Segars JH Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril. 2004 ; 82 (suppl 3). 1182-1187.
2. Catherino WH, Leppert PC, Stenmark MH, et al. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer. 2004 ; 40 (3). 204-217.
3. Leppert PC, Catherino WH, Segars JH A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol. 2006 ; 195 (2). 415-420.
4. Stewart EA, Nowak RA New concepts in the treatment of uterine leiomyomas. Obstet Gynecol. 1998 ; 92 (4 pt 1). 624-627.
5. Dours-Zimmermann MT, Zimmermann DR A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem. 1994 ; 269 (52). 32992-32998.
6. LeBaron RG, Zimmermann DR, Ruoslahti E. Hyaluronate binding properties of versican. J Biol Chem. 1992 ; 267 (14). 10003-10010.
7. Zimmermann DR, Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J. 1989 ; 8 (10). 2975-2981.
8. Evanko SP, Johnson PY, Braun KR, Underhill CB, Dudhia J., Wight TN Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. Arch Biochem Biophys. 2001 ; 394 (1). 29-38.
9. Aspberg A., Miura R., Bourdoulous S., et al. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. Proc Natl Acad Sci U S A. 1997 ; 94 (19). 10116-10121.
10. Aspberg A., Adam S., Kostka G., Timpl R., Heinegard D. Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem. 1999 ; 274 (29). 20444-20449.
11. Olin AI, Morgelin M., Sasaki T., Timpl R., Heinegard D., Aspberg A. The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding. J Biol Chem. 2001 ; 276 (2). 1253-1261.
12. Isogai Z., Aspberg A., Keene DR, Ono RN, Reinhardt DP, Sakai LY Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J Biol Chem. 2002 ; 277 (6). 4565-4572.
13. Yamagata M., Yamada KM, Yoneda M., Suzuki S., Kimata K. Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem. 1986 ; 261 (29). 13526-13535.
14. Kawashima H., Hirose M., Hirose J., Nagakubo D., Plaas AH, Miyasaka M. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem. 2000 ; 275 (45). 35448-35456.
15. Kawashima H., Atarashi K., Hirose M., et al. Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1- 3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines. J Biol Chem. 2002 ; 277 (15). 12921-12930.
16. Wu Y., Chen L., Zheng PS, Yang BB beta 1-Integrinmediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem. 2002 ; 277 (14). 12294-12301.
17. Bajorath J., Greenfield B., Munro SB, Day AJ, Aruffo A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem. 1998 ; 273 (1). 338-343.
18. Wu Y., Sheng W., Chen L., et al. Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. Mol Biol Cell. 2004 ; 15 (5). 2093-2104.
19. Zheng PS, Wen J., Ang LC, et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J. 2004 ; 18 (6). 754-756.
20. Ricciardelli C., Quinn DI, Raymond WA, et al. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 1999 ; 59 (10). 2324-2328.
21. Ricciardelli C., Brooks JH, Suwiwat S., et al. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res. 2002 ; 8 (4). 1054-1060.
22. Naso MF, Zimmermann DR, Iozzo RV Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem. 1994 ; 269 (52). 32999-33008.
23. Wight TN Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002 ; 14 (5). 617-623.
24. Corps AN, Robinson AH, Movin T., et al. Versican splice variant messenger RNA expression in normal human Achilles tendon and tendinopathies. Rheumatology (Oxford). 2004 ; 43 (8). 969-972.
25. Wu YJ, La Pierre DP, Wu J., Yee AJ, Yang BB The interaction of versican with its binding partners. Cell Res. 2005 ; 15 (7). 483-494.
26. Cattaruzza S., Schiappacassi M., Ljungberg-Rose A., et al. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem. 2002 ; 277 (49). 47626-47635.
27. Kamiya N., Watanabe H., Habuchi H., et al. Versican/PG-M regulates chondrogenesis as an extracellular matrix molecule crucial for mesenchymal condensation. J Biol Chem. 2006 ; 281 (4). 2390-2400.
28. Westergren-Thorsson G., Norman M., Bjornsson S., et al. Differential expressions of mRNA for proteoglycans, collagens and transforming growth factor-beta in the human cervix during pregnancy and involution. Biochim Biophys Acta. 1998 ; 1406 (2). 203-213.
29. Ryu KY, Mahendroo M. Regulated changes in crosslinks between versican and hyaluronan may facilitate cervical ripening. Reprod Sci. 2007 ; 14 (Suppl 1). 68.
30. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990 ; 6: 597-641.
31. He W., Dorn DC, Erdjument-Bromage H., Tempst P., Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell. 2006 ; 125 (5). 929-941.
32. Lee BS, Nowak RA Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab. 2001 ; 86 (2). 913-920.
33. Luo X., Ding L., Xu J., Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology. 2005 ; 146 (3). 1097-1118.
34. Stewart EA, Disalvo D., Sharif NA, Sultana N., Margolin SB Pirfenidone for the treatment of uterine leiomyomas: pilot study data. J Soc Gynecolog Invest. 1999 ; 6: 229A.
35. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006 ; 69 (2). 213-217. (Pubitemid 43323069)
36. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007 ; 293 (3). L525-534.
37. Yata Y., Gotwals P., Koteliansky V., Rockey DC Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology. 2002 ; 35 (5). 1022-1030.
38. Verrecchia F., Mauviel A., Farge D. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev. 2006 ; 5 (8). 563-569.
39. Bierie B., Moses HL Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006 ; 6 (7). 506-520.
40. Bonniaud P., Margetts PJ, Ask K., Flanders K., Gauldie J., Kolb M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol. 2005 ; 175 (8). 5390-5395.
41. Derynck R., Lindquist PB, Lee A., et al. A new type of transforming growth factor-beta, TGF-beta 3. EMBO J. 1988 ; 7 (12). 3737-3743.
42. Tang XM, Dou Q., Zhao Y., McLean F., Davis J., Chegini N. The expression of transforming growth factor-beta s and TGF-beta receptor mRNA and protein and the effect of TGF-beta s on human myometrial smooth muscle cells in vitro. Mol Hum Reprod. 1997 ; 3 (3). 233-240.
43. Arici A., Sozen I. Transforming growth factor-beta3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation. Fertil Steril. 2000 ; 73 (5). 1006-1011.
44. Vollenhoven BJ, Herington AC, Healy DL Epidermal growth factor and transforming growth factor-beta in uterine fibroids and myometrium. Gynecol Obstet Invest. 1995 ; 40 (2). 120-124.
45. Malik M., Catherino WH Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays. Fertil Steril. 2007 ; 87 (5). 1166-1172.
46. Catherino WH, Prupas C., Tsibris JC, et al. Strategy for elucidating differentially expressed genes in leiomyomata identified by microarray technology. Fertil Steril. 2003 ; 80 (2). 282-290.
47. Malik M., Webb J., Catherino WH Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol (Oxf). 2008 ; 69 (3). 462-470.
48. Rhim JS Generation of immortal human prostate cell lines for the study of prostate cancer. Methods Mol Med. 2003 ; 81: 69-77.
49. Levens E., Luo X., Ding L., Williams RS, Chegini N. Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling. Mol Hum Reprod. 2005 ; 11 (7). 489-494.
50. Xu J., Luo X., Chegini N. Differential expression, regulation, and induction of Smads, transforming growth factor-beta signal transduction pathway in leiomyoma, and myometrial smooth muscle cells and alteration by gonadotropin-releasing hormone analog. J Clin Endocrinol Metab. 2003 ; 88 (3). 1350-1361.
51. Tsibris JC, Segars J., Coppola D., et al. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril. 2002 ; 78 (1). 114-121.
52. Pfaffl MW A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001 ; 29 (9). e45.
53. Fleisch MC, Maxwell CA, Barcellos-Hoff MH The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr Relat Cancer. 2006 ; 13: 379-400.
54. Rogers R., Norian J., Malik M., et al. Mechanical homeostasis is altered in uterine leiomyoma. Am J Obstet Gynecol. 2008 ; 198 (4). 474.e471-411.
55. Wolanska M., Sobolewski K., Drozdzewicz M., Bankowski E. Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth. Mol Cell Biochem. 1998 ; 189 (1-2). 145-152.
56. Mitropoulou TN, Theocharis AD, Stagiannis KD, Karamanos NK Identification, quantification and fine structural characterization of glycosaminoglycans from uterine leiomyoma and normal myometrium. Biochimie. 2001 ; 83 (6). 529-536.
57. Berto AG, Sampaio LO, Franco CR, Cesar RM Jr, Michelacci YM A comparative analysis of structure and spatial distribution of decorin in human leiomyoma and normal myometrium. Biochim Biophys Acta. 2003 ; 1619 (1). 98-112.
58. Paszek MJ, Zahir N., Johnson KR, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005 ; 8 (3). 241-254.
59. Keller R., Davidson LA, Shook DR How we are shaped: the biomechanics of gastrulation. Differentiation. 2003 ; 71 (3). 171-205.
60. Engler AJ, Griffin MA, Sen S., Bonnemann CG, Sweeney HL, Discher DE Myotubes differentiate optimally on substrates with tissue-like stiffness: pathological implications for soft or stiff microenvironments. J Cell Biol. 2004 ; 166 (6). 877-887.
61. Stewart EA, Friedman AJ, Peck K., Nowak RA Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab. 1994 ; 79 (3). 900-906.
62. Luo X., Ding L., Chegini N. CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-beta and regulation by TGF-beta in leiomyoma and myometrial smooth muscle cells. Mol Hum Reprod. 2006 ; 12 (4). 245-256.
63. Sozen I., Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril. 2002 ; 78 (1). 1-12.
64. Sozen I., Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin North Am. 2006 ; 33 (1). 41-58.
65. Wight TN, Merrilees MJ Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res. 2004 ; 94 (4). 1158-1167.
66. Huang R., Merrilees MJ, Braun K., et al. Inhibition of versican synthesis by antisense alters smooth muscle cell phenotype and induces elastic fiber formation in vitro and in neointima after vessel injury. Circ Res. 2006 ; 98 (3). 370-377.
67. Lemire JM, Merrilees MJ, Braun KR, Wight TN Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol. 2002 ; 190 (1). 38-45.
68. McCarthy S., Scott G., Majumdar S., et al. Uterine junctional zone: MR study of water content and relaxation properties. Radiology. 1989 ; 171 (1). 241-243.
69. Blobe GC, Schiemann WP, Lodish HF Role of transforming growth factor beta in human disease. N Engl J Med. 2000 ; 342 (18). 1350-1358.
70. Moustakas A., Souchelnytskyi S., Heldin CH Smad regulation in TGF-beta signal transduction. J Cell Sci. 2001 ; 114 (pt 24). 4359-4369.
71. Massague J., Wotton D. Transcriptional control by the TGFbeta/Smad signaling system. EMBO J. 2000 ; 19 (8). 1745-1754.
72. ten Dijke P., Hill CS New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004 ; 29 (5). 265-273.
73. Chegini N., Luo X., Ding L., Ripley D. The expression of Smads and transforming growth factor beta receptors in leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. Mol Cell Endocrinol. 2003 ; 209 (1-2). 9-16.
74. Arslan AA, Gold LI, Mittal K., et al. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod. 2005 ; 20 (4). 852-863.